Amgen Faces Potential Lack Of Near-Commercial Assets
Company’s Q3 Call Likely To Focus On Pipeline, Not Sales
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
